PT  - JOURNAL ARTICLE
AU  - Gunderao H Kathwate
TI  - <em>In Silico</em> design and characterization of multiepitopes vaccine for SARS-CoV2 from its Spike proteins
AID  - 10.1101/2020.06.03.131755
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.06.03.131755
4099  - http://biorxiv.org/content/early/2020/06/06/2020.06.03.131755.short
4100  - http://biorxiv.org/content/early/2020/06/06/2020.06.03.131755.full
AB  - COVID 19 is disease caused by novel corona virus, SARS-CoV2 originated in China most probably of Bat origin. Till date, no specific vaccine or drug has been discovered to tackle the infections caused by SARS-CoV2. In response to this pandemic, we utilized bioinformatics knowledge to develop efficient vaccine candidate against SARS-CoV2. Designed vaccine is rich in effective BCR and TCR epitopes screened from the sequence of S-protein of SARS-CoV2. Bioinformatics tools were utilized for prediction, refinement and validation of tertiary structure of designed vaccine. Protein-Protein interaction prediction of TLR2/4 and designed vaccine indicate effective binding. Designed multiepitopes vaccine has induce cell mediated and humoral immunity along with increased interferon gamma response. Macrophages and dendritic cells were also found increased over the vaccine exposure. In silico codon optimization and cloning in expression vector indicate that vaccine can be efficiently expressed in E. coli. In conclusion, predicted vaccine is a good antigen, probable no allergen and has potential to induce cellular and humoral immunity.Competing Interest StatementThe authors have declared no competing interest.